Abstract
We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in
Original language | English |
---|---|
Pages (from-to) | 257-265 |
Number of pages | 9 |
Journal | Hematol. Oncol. |
Volume | 38 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- cell of origin
- diffuse large B-cell lymphoma
- immunomodulators
- lenalidomide
- maintenance
- transformed high-grade lymphoma
- angiogenesis inhibitor
- adult
- aged
- anemia
- Article
- autologous stem cell transplantation
- cancer chemotherapy
- cancer immunotherapy
- cancer recurrence
- clinical article
- constipation
- diarrhea
- diffuse large B cell lymphoma
- drug efficacy
- drug safety
- febrile neutropenia
- female
- follow up
- human
- liver toxicity
- male
- multicenter study
- nausea and vomiting
- nephrotoxicity
- neurotoxicity
- neutropenia
- phase 2 clinical trial
- priority journal
- progression free survival
- rash
- salvage therapy
- thrombocytopenia
- thrombosis
- treatment failure
- treatment response
- clinical trial
- maintenance chemotherapy
- middle aged
- pathology
- prognosis
- survival rate
- tumor recurrence
- very elderly
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
- Female
- Follow-Up Studies
- Humans
- Lenalidomide
- Lymphoma, Large B-Cell, Diffuse
- Maintenance Chemotherapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Prognosis
- Salvage Therapy
- Survival Rate